The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 12, 2016
Filed:
Nov. 21, 2014
Applicant:
Trustees of Dartmouth College, Hanover, NH (US);
Inventors:
Ta-Yuan Chang, Etna, NH (US);
Catherine C. Y. Chang, Etna, NH (US);
Yohei Shibuya, West Lebanon, NH (US);
Zhaoyang Niu, Hanover, NH (US);
Assignee:
Trustees of Dartmouth College, Hanover, NH (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61P 25/28 (2006.01); C12N 15/113 (2010.01); A61K 35/761 (2015.01); C12N 7/00 (2006.01); A61K 31/44 (2006.01); A61K 31/255 (2006.01); A61K 31/167 (2006.01); A61K 31/395 (2006.01); A61K 31/415 (2006.01); A61K 31/496 (2006.01); A61K 31/55 (2006.01); A61K 31/70 (2006.01); A61K 31/7105 (2006.01); A61K 31/713 (2006.01); A61K 49/00 (2006.01); A61K 48/00 (2006.01); A61K 9/127 (2006.01);
U.S. Cl.
CPC ...
C12N 15/1137 (2013.01); A61K 31/167 (2013.01); A61K 31/255 (2013.01); A61K 31/395 (2013.01); A61K 31/415 (2013.01); A61K 31/44 (2013.01); A61K 31/496 (2013.01); A61K 31/55 (2013.01); A61K 31/70 (2013.01); A61K 31/713 (2013.01); A61K 31/7105 (2013.01); A61K 35/761 (2013.01); A61K 49/0008 (2013.01); C12N 7/00 (2013.01); C12Y 203/01009 (2013.01); A61K 9/127 (2013.01); A61K 48/00 (2013.01); C12N 2310/14 (2013.01); C12N 2310/141 (2013.01); C12N 2710/10042 (2013.01); C12N 2710/10071 (2013.01);
Abstract
The present invention features methods for stimulating clearance of misfolded or aggregated proteins or peptides in microglia or neurons, and treating neurodegenerative diseases associated with such pathology in brain by selectively inhibiting the expression or activity of Acyl-CoA:Cholesterol Acyltransferase 1, but not Acyl-CoA:Cholesterol Acyltransferase 2.